Asmaa M Zahran1, Omnia El-Badawy2, Wageeh A Ali3, Zainab Gaber Mahran4, Essam Eldeen M O Mahran4, Amal Rayan5. 1. Department of Clinical Pathology, South Egypt Cancer Institute, Assiut University, Assiut, Egypt. 2. Department of Medical Microbiology and Immunology, Faculty of Medicine, Assiut University, Assiut, Egypt. 3. Diagnostic and Interventional Radiology Department, Faculty of Medicine, Assiut University, Assiut, Egypt. 4. Department of Tropical Medicine and Gastroenterology, Faculty of Medicine, Assiut University, Assiut, Egypt. 5. Clinical Oncology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
Abstract
BACKGROUND AND AIM: The study aimed to determine whether the MPs levels and platelet activation are affected by the COVID-19 infection in both malignant and non-malignant patients compared to healthy individuals and define their contribution to the COVID-19 associated coagulopathy and the relation of these MPs to other hematologic parameters. PATIENTS AND METHODS: We recruited 23 malignant patients with reverse transcription polymerase chain reaction (RT-PCR) positive COVID-19, also, 19 COVID-19 non-malignant patients, and 20 healthy volunteers were also enrolled for comparison. Blood samples were collected from patients and healthy donors into 5 mL vacutainer tube containing 3.5% buffered sodium citrate solution for measurement of total microparticles (TMPs), platelet microparticles (PMPs), endothelial microparticles (EMPs), CD62 activated platelets, and CD41 platelet marker. RESULTS: COVID-19 malignant patients had significantly lower hemoglobin and platelets compared to COVID non-malignant ones, while they had significantly higher C-reactive protein, LDH, AST, Albunim, creatinine, and prognostic index (PI) compared to COVID-19 non-malignant patients. significant accumulations of TMPs, PMPs, EMPs, and activated platelets in COVID-19 affected patients compared to healthy controls. TMPs, and EMPs were significantly accumulated in COVID-19 malignant compared to COVID-19 non-malignant patients with no significant difference in PMPs between both. CONCLUSION: Circulating MPs and activated platelets may be promising novel prognostic biomarkers capable of identifying potentially severe COVID-19 patients who require immediate care especially in cancer patients.
BACKGROUND AND AIM: The study aimed to determine whether the MPs levels and platelet activation are affected by the COVID-19infection in both malignant and non-malignant patients compared to healthy individuals and define their contribution to the COVID-19 associated coagulopathy and the relation of these MPs to other hematologic parameters. PATIENTS AND METHODS: We recruited 23 malignant patients with reverse transcription polymerase chain reaction (RT-PCR) positive COVID-19, also, 19 COVID-19 non-malignant patients, and 20 healthy volunteers were also enrolled for comparison. Blood samples were collected from patients and healthy donors into 5 mL vacutainer tube containing 3.5% buffered sodium citrate solution for measurement of total microparticles (TMPs), platelet microparticles (PMPs), endothelial microparticles (EMPs), CD62 activated platelets, and CD41 platelet marker. RESULTS:COVID-19 malignant patients had significantly lower hemoglobin and platelets compared to COVID non-malignant ones, while they had significantly higher C-reactive protein, LDH, AST, Albunim, creatinine, and prognostic index (PI) compared to COVID-19 non-malignant patients. significant accumulations of TMPs, PMPs, EMPs, and activated platelets in COVID-19 affected patients compared to healthy controls. TMPs, and EMPs were significantly accumulated in COVID-19 malignant compared to COVID-19 non-malignant patients with no significant difference in PMPs between both. CONCLUSION: Circulating MPs and activated platelets may be promising novel prognostic biomarkers capable of identifying potentially severe COVID-19patients who require immediate care especially in cancerpatients.
Authors: Hassan A Hamali; Muhammad Saboor; Gasim Dobie; Aymen M Madkhali; Mohammad S Akhter; Ali Hakamy; Hesham M Al-Mekhlafi; Denise E Jackson; Yahya H Matari; Abdullah A Mobarki Journal: Infect Drug Resist Date: 2022-04-29 Impact factor: 4.177
Authors: Rebekah Penrice-Randal; Xiaofeng Dong; Andrew George Shapanis; Aaron Gardner; Nicholas Harding; Jelmer Legebeke; Jenny Lord; Andres F Vallejo; Stephen Poole; Nathan J Brendish; Catherine Hartley; Anthony P Williams; Gabrielle Wheway; Marta E Polak; Fabio Strazzeri; James P R Schofield; Paul J Skipp; Julian A Hiscox; Tristan W Clark; Diana Baralle Journal: Front Immunol Date: 2022-09-20 Impact factor: 8.786